Healthcare / BiotechnologyNasdaqGS
$2.33
-0.10 (-3.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-112.4M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$232M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-121.2%
↓Gross Margin
N/A
•Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+11.6%
FCF CAGR
—
FCF margin
-1006.8%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.2M · net income $-148.1M · FCF $-112.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $11.2M | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M | $12.4M | $5.8M |
| Net Income | $-148.1M | $-148.1M | $-149.1M | $-102.1M | $-99.4M | $-66.9M | $-34.3M | $-23.4M |
| EBITDA | $-132.5M | $-132.5M | $-162.7M | $-112.5M | $-104.8M | $-66.0M | $-35.2M | $-33.6M |
| EPS | -1.59 | -1.59 | -1.65 | -1.38 | -1.64 | -2.11 | — | — |
| Operating Margin | -1220.5% | -1220.5% | -1667.2% | -336.6% | -768.2% | -697.8% | -292.2% | -592.7% |
| Net Margin | -1327.4% | -1327.4% | -1491.9% | -296.1% | -717.8% | -697.3% | -277.6% | -404.8% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.22 | 0.22 | 0.10 | 0.07 | 0.09 | — | — | — |
| Current Ratio | 6.22 | 6.22 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-112.4M | $-112.4M | $-144.7M | $-104.9M | $-98.0M | $-34.6M | $-33.5M | $-32.9M |
| Returns | ||||||||
| ROE | -121.2% | -121.2% | -58.9% | -27.7% | -33.0% | -17.3% | 146.4% | -314.0% |
| Valuation | ||||||||
| P/B | 1.78 | 1.78 | 0.61 | 0.97 | 1.39 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 11.7% | 11.7% | -71.0% | 148.9% | — | -22.4% | 113.6% | — |
| EPS Growth | 3.6% | 3.6% | -19.6% | 15.9% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+139.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.65 → -1.59
Residual
+139.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.